October 2021 FDA Recall Drug by Merck Sharp & Dohme Corp
D-0093-2022 - Presence of Particulate Matter

This Class I drug recall was voluntarily initiated by Merck Sharp & Dohme Corp on October 19, 2021 for the product Drug. The FDA reported the reason for recall as presence of particulate matter. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0093-2022

Reason for Recall
Presence of Particulate Matter: Identified as Glass Particles
Initiated
10-19-2021
Reported
11-10-2021
Quantity
76,163 vials

Recall Profile & Regulatory Data

Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
MERCK SHARP & DOHME CORP
Nationwide within the United States
Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01

Batch or Lot Expiration Information

Lot# : 934778, Exp. Date Jun 2022